Dan Rose

New Capabilities

Leading commercial launch of the Hēlo platform

The FDA cleared two devices that together form a pulmonary embolism thrombectomy platform with integrated blood return. Endovascular Engineering's Hēlo system removes clots from the lungs while filtering and returning the patient's own blood, cutting median blood loss by 97% in the ENGULF trial.

Updated Oct 12